OSI-906 (Linsitinib) 化学構造
分子量: 421.49

高品質保証

カスタマーフィードバック(3)

Quality Control & MSDS

製品説明

  • Compare IGF-1R Inhibitors
    IGF-1R製品生物活性の比較
  • 研究分野

製品の説明

生物活性

製品説明 OSI-906(Linsitinib)は、IGF-IRとIrの選択的な阻害剤で、IC50 がそれぞれ 35 nM と 75 nMです。
ターゲット IGF-1R InsR
IC50 35 nM 75 nM [1]
In vitro試験 OSI-906 inhibits IGF-1R autophosphorylation and activation of the downstream signaling proteins Akt, ERK1/2 and S6 kinase with IC50 of 0.028 to 0.13 μM. OSI-906 enables an intermediate conformation of the target protein through interactions with the C-helix. OSI-906 displays favorable metabolic stability in liver microsomes. OSI-906 fully inhibits both IR and IGF-1R phosphorylation at a concentration of 1 μM. OSI-906 inhibits proliferation of several tumor cell lines including non-small-cell lung cancer and colorectal cancer (CRC) tumor cell line with EC50 of 0.021 to 0.810 μM. [1]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
A4-Fuk Mm\LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkXSTWM2OD1yLkCyPFA3KM7:TR?= Mme3V2FPT0WU
KS-1 M2\Fb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX\RVIJqUUN3ME2wMlA{QDN3IN88US=> M1rQfXNCVkeHUh?=
TE-11 NWjUVXNpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn7sTWM2OD1yLkC3PFIzKM7:TR?= MmH4V2FPT0WU
EW-1 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2[yV2lEPTB;MD6wPFU5PSEQvF2= NVnNfJRqW0GQR1XS
HMV-II MkDuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3fyS2lEPTB;MD6wPFg1PiEQvF2= MUPTRW5ITVJ?
COLO-205 M2LnSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlrZTWM2OD1yLkGwOFU1KM7:TR?= NWjGWJc4W0GQR1XS
ES1 M1zGUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm[yTWM2OD1yLkGwOlk3KM7:TR?= M3PyU3NCVkeHUh?=
GDM-1 NVPycoR6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{K2NWlEPTB;MD6xN|Y4OiEQvF2= NV7Oe5ZsW0GQR1XS
ML-2 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYjpPHJkUUN3ME2wMlE2QDl4IN88US=> M4\0XnNCVkeHUh?=
Saos-2 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTBwMU[1NlYh|ryP NUjxRpVSW0GQR1XS
NCI-H1355 NIrxRnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2DHcWlEPTB;MD6xPFE{PSEQvF2= NHy4WJBUSU6JRWK=
G-401 MnLzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmDlTWM2OD1yLkG4NlMh|ryP MYrTRW5ITVJ?
EW-16 NYnjeJFDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MofITWM2OD1yLkG4O|c4KM7:TR?= NEnmO3FUSU6JRWK=
EW-7 MnP3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MorqTWM2OD1yLkG4PFgyKM7:TR?= MWHTRW5ITVJ?
NCI-H727 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4HDUWlEPTB;MD6xPVc6PCEQvF2= NYnoNIM4W0GQR1XS
LCLC-97TM1 NX:4[XNQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXXJR|UxRTBwMkC5OVUh|ryP MkfNV2FPT0WU
NCI-H650 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXrrNoZUUUN3ME2wMlIyOzh2IN88US=> MlfWV2FPT0WU
NCI-H2122 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkXFTWM2OD1yLkKzNlk6KM7:TR?= NEXoXVZUSU6JRWK=
SK-N-DZ NEjS[XJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MknmTWM2OD1yLkKzOlk5KM7:TR?= NVPB[HlFW0GQR1XS
HT-29 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{X4bGlEPTB;MD6yOFI1QCEQvF2= NGntfmhUSU6JRWK=
LB771-HNC NV\wfZZoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUizdno2UUN3ME2wMlI2QTF3IN88US=> M4nIW3NCVkeHUh?=
HT-144 MmfoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1jwN2lEPTB;MD6yOlE6OSEQvF2= Ml;2V2FPT0WU
LAN-6 M1zHR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUm0fldLUUN3ME2wMlI3OzR6IN88US=> MoHKV2FPT0WU
EW-18 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWrJR|UxRTBwMkewNFEh|ryP NUTlUJg3W0GQR1XS
LS-1034 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnTRTWM2OD1yLkK3NVMzKM7:TR?= MVfTRW5ITVJ?
EW-11 M3LlUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MljjTWM2OD1yLkK4OFMzKM7:TR?= MnXHV2FPT0WU
SNU-C1 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIfoW4RKSzVyPUCuNlk{OTNizszN NGHzbFlUSU6JRWK=
RS4-11 NF\KUZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVnJR|UxRTBwM{O3OVgh|ryP MU\TRW5ITVJ?
ES4 NYC5dlVWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWjJR|UxRTBwNEGwN|gh|ryP NFnuV2RUSU6JRWK=
COLO-320-HSR Mn;xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmTFTWM2OD1yLkSxN|Y5KM7:TR?= NHq0VZBUSU6JRWK=
NB10 MmfhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MW\JR|UxRTBwNEW0N|ch|ryP MlPSV2FPT0WU
BFTC-905 MkG4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWjKU2p7UUN3ME2wMlQ3PzV6IN88US=> MX3TRW5ITVJ?
A375 NHLMZZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX3NTIhJUUN3ME2wMlQ4PjF5IN88US=> Mn:4V2FPT0WU
SJRH30 NGLoNWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFHuZoJKSzVyPUCuOVA5OjJizszN MXHTRW5ITVJ?
NOS-1 MkGzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\TWnpKSzVyPUCuOVIzPjdizszN NHTZeZJUSU6JRWK=
SIG-M5 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{SxR2lEPTB;MD61N|U2PyEQvF2= NF\wV5BUSU6JRWK=
DOK M4T5dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHviO4VKSzVyPUCuOVU3KM7:TR?= M1nQTnNCVkeHUh?=
NB69 M4jx[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnfuTWM2OD1yLkW4NlU4KM7:TR?= NU\Tb4ttW0GQR1XS
SK-NEP-1 NXHoN4ZFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1KzPWlEPTB;MD62NFI{PiEQvF2= NGWwT3NUSU6JRWK=
SK-MM-2 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWTJR|UxRTBwNkW0PVEh|ryP NW\1eHRlW0GQR1XS
NCI-H358 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTBwNkewPFIh|ryP MWTTRW5ITVJ?
RH-1 MoXQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHnNUIJKSzVyPUCuO|Q5PTlizszN MV\TRW5ITVJ?
NH-12 NHXYNWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV\JR|UxRTBwN{[wOFYh|ryP MW\TRW5ITVJ?
TE-12 NYLGcmNpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M17oU2lEPTB;MD63OlQ5PiEQvF2= NUjDXphVW0GQR1XS
COLO-668 NW\JOHFET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4XqdGlEPTB;MD64OFY3PiEQvF2= MXvTRW5ITVJ?
PANC-08-13 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTBwOE[zO|ch|ryP MV3TRW5ITVJ?
HCC2998 M2XHSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2Ht[2lEPTB;MD64PFI3OyEQvF2= MkfFV2FPT0WU
ABC-1 M4KzPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoniTWM2OD1yLkmwN|UzKM7:TR?= NF7BNlBUSU6JRWK=
ES6 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXzJR|UxRTBwOUGwOlYh|ryP M4fkSnNCVkeHUh?=
SNU-387 NGXjUpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEnUXIhKSzVyPUCuPVk{QTNizszN M2PQ[XNCVkeHUh?=
CMK M{CzNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUjqVI4xUUN3ME2wMlk6QTJ7IN88US=> MUnTRW5ITVJ?
SJSA-1 NELCUYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{XMcWlEPTB;MT6wN|Y2OyEQvF2= M{fw[nNCVkeHUh?=
SIMA Mn;GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRTFwME[4NlUh|ryP NG\qOIFUSU6JRWK=
ES3 NYfwXIhiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXfPN25kUUN3ME2xMlEzOjl5IN88US=> MoC4V2FPT0WU
IGROV-1 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3nHVWlEPTB;MT6xOVQ1PCEQvF2= MVLTRW5ITVJ?
MEL-JUSO MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFrjT2xKSzVyPUGuNVU4PTlizszN M13RR3NCVkeHUh?=
T84 NUTLWnQ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{fwSWlEPTB;MT6yNFkyPCEQvF2= MlX2V2FPT0WU
CAL-85-1 NGrnUIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkL1TWM2OD1zLkKzNVM5KM7:TR?= MlHZV2FPT0WU
RD MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoDVTWM2OD1zLkK2OFU2KM7:TR?= NFvs[XhUSU6JRWK=
TE-8 M4H2U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkC2TWM2OD1zLkOxOFYzKM7:TR?= NIXiWlVUSU6JRWK=
L-363 M{X6c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkHkTWM2OD1zLkO0NlA5KM7:TR?= NVuxNXZMW0GQR1XS
EKVX MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NInM[m1KSzVyPUGuN|Q2PjhizszN NIjyWXhUSU6JRWK=
SK-MEL-3 MnLjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVvJR|UxRTFwNEi1OVYh|ryP NUDM[3ZDW0GQR1XS
TGBC24TKB MoS2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{m4c2lEPTB;MT61NFE6OyEQvF2= NVz2[5l2W0GQR1XS
NCI-H1770 NXH4XnlWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVT2[YRJUUN3ME2xMlUyOTF|IN88US=> MVHTRW5ITVJ?
HuH-7 NV\0XotST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3O5XGlEPTB;MT62NFA6QCEQvF2= M{C0XHNCVkeHUh?=
HL-60 M4\Pc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWrJR|UxRTFwNk[5Nlgh|ryP NUe0cFVzW0GQR1XS
TE-1 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MorQTWM2OD1zLkewPVQ2KM7:TR?= MkTJV2FPT0WU
LC-2-ad M3[4Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXe5foNRUUN3ME2xMlc{QDh5IN88US=> MYnTRW5ITVJ?
LB647-SCLC NUnkcmh7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1\iOGlEPTB;MT63OlU5OyEQvF2= MmPOV2FPT0WU
NCI-H2171 M37ON2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmPUTWM2OD1zLke3O|E3KM7:TR?= M2fifXNCVkeHUh?=
SK-PN-DW MkXnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYrNXYdsUUN3ME2xMlkyOjl6IN88US=> MYrTRW5ITVJ?
MC-IXC NUDXR|N3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHrYUoxKSzVyPUGuPVg6QCEQvF2= M17PbnNCVkeHUh?=
LS-513 NGDQc3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWHJR|UxRTJwMEWzNFUh|ryP NWPGcnBsW0GQR1XS
EW-3 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2XD[GlEPTB;Mj6wPVg1PCEQvF2= NYXwVWwxW0GQR1XS
OPM-2 NGDPenJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYjoXHU1UUN3ME2yMlExOiEQvF2= NX7Gd4VUW0GQR1XS
LP-1 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{\jVGlEPTB;Mj6yOVgxPyEQvF2= MljJV2FPT0WU
LU-134-A MmrWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHrzVGFKSzVyPUKuNlc4KM7:TR?= M3G1SXNCVkeHUh?=
CP66-MEL NXHlbJNjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{jWXmlEPTB;Mj6yPVAyPCEQvF2= MmnoV2FPT0WU
HCC1143 Mo\iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGjsbpBKSzVyPUKuOFU{PjhizszN MUfTRW5ITVJ?
LOXIMVI NYHiS|YzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVHreY11UUN3ME2yMlYxOjFizszN NUDiOoNQW0GQR1XS
TE-10 NUf4[3I2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2DwZ2lEPTB;Mj63NFg{QCEQvF2= MUPTRW5ITVJ?
NCI-H1882 M3LxSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4\aVWlEPTB;Mj63OVIzPyEQvF2= MVzTRW5ITVJ?
CHP-126 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXvJR|UxRTJwN{[zNVch|ryP MWHTRW5ITVJ?
NCI-H1623 MnWyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFPDV4pKSzVyPUKuPVIxOjRizszN NFrWUmFUSU6JRWK=
GB-1 M{THd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{\jcmlEPTB;Mj65N|QxPCEQvF2= MmDsV2FPT0WU
RCC10RGB NE\xfXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFTHUWtKSzVyPUKuPVUzQDFizszN MUDTRW5ITVJ?
NCI-H2141 M{HKeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkXyTWM2OD1{Lkm2PFk3KM7:TR?= NX;6UGRMW0GQR1XS
GI-ME-N M1nifWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYPQcpRwUUN3ME2zMlAxPTZ3IN88US=> M3X1SnNCVkeHUh?=
NCI-H526 NYq5ZoJYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHWxTYJKSzVyPUOuNFQxQDVizszN MnHsV2FPT0WU
NCI-H747 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTNwMES5PVIh|ryP NFO3[IJUSU6JRWK=
SNU-423 NEjTd4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEnpOo5KSzVyPUOuNlA{OTNizszN M1jpbnNCVkeHUh?=
A427 MlvpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV7JR|UxRTNwMkW2PVkh|ryP M1P6N3NCVkeHUh?=
CAL-12T NVPIVIxbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MofJTWM2OD1|LkSwO|E{KM7:TR?= M2nRdXNCVkeHUh?=
LU-99A MonNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYrVR|ZCUUN3ME2zMlQ4OTB3IN88US=> NHf5N4FUSU6JRWK=
MS-1 M3SySWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXzOfZY3UUN3ME2zMlU{PDJ7IN88US=> M4DIWnNCVkeHUh?=
SK-LU-1 MnTBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2ftc2lEPTB;Mz63OlI6PSEQvF2= M2\lb3NCVkeHUh?=
SW837 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEnwcHpKSzVyPUOuO|Y{OzNizszN M1Hv[3NCVkeHUh?=
ES8 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWfJR|UxRTNwOEO4O|ch|ryP Mkn2V2FPT0WU
MZ2-MEL NFLVVpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYPXWo5vUUN3ME2zMlkzODh4IN88US=> MXTTRW5ITVJ?
TGW M1HTVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIrVOJhKSzVyPUSuNFE{OTFizszN MULTRW5ITVJ?
GP5d M1vxZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUPJR|UxRTRwMEWzOlIh|ryP NE\QTYVUSU6JRWK=
BB49-HNC NVTyOWJRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlPYTWM2OD12LkG1NlE{KM7:TR?= MWrTRW5ITVJ?
NB13 Mk\vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1nSZWlEPTB;ND6yOlg5PyEQvF2= M3q4TnNCVkeHUh?=
NTERA-S-cl-D1 MlTHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXnJR|UxRTRwMki2NVUh|ryP M1q0T3NCVkeHUh?=
NCI-H1648 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXrzeIZFUUN3ME20MlI6QDF7IN88US=> MWTTRW5ITVJ?
LCLC-103H NXe2fncxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mln2TWM2OD12LkOyNVk2KM7:TR?= M{H1RnNCVkeHUh?=
LS-411N NIfkfXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXq4W5ZGUUN3ME20MlQ1QDh3IN88US=> NVfVPWxmW0GQR1XS
NCI-H1092 M4ewd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFW4R2RKSzVyPUSuOFU3QDdizszN M4[5SnNCVkeHUh?=
PANC-10-05 NIfLWWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3;4[mlEPTB;ND62PVg1KM7:TR?= MY\TRW5ITVJ?
DK-MG M1zCO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIHzU4ZKSzVyPUSuPFA6OzNizszN NX;xNFJJW0GQR1XS
OVCAR-5 Mo\RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRTRwOEGyNlYh|ryP M333T3NCVkeHUh?=
CAL-39 NWOzcYNMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUDpd41rUUN3ME20Mlg4PjdizszN NHnLbYZUSU6JRWK=
TE-441-T NVHiXZFNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NILnUJFKSzVyPUSuPVA2OzdizszN NIfrVJhUSU6JRWK=
MOLT-16 NWfWVW16T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NITlb3NKSzVyPUSuPVUzPTNizszN NIT1eoFUSU6JRWK=
MCF7 Mo\TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUO0fGpRUUN3ME21MlE1PTF5IN88US=> MVzTRW5ITVJ?
CAPAN-1 M1\DS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnvuTWM2OD13LkK1O|A4KM7:TR?= M{Pmd3NCVkeHUh?=
PSN1 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUnrfHloUUN3ME21MlI4OjN3IN88US=> NWTBPJQyW0GQR1XS
NCI-H292 NWnjXpY4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlXXTWM2OD13LkOwNFQ1KM7:TR?= NHHx[2ZUSU6JRWK=
CPC-N M1LLbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2OyXGlEPTB;NT6zPVQyQSEQvF2= NHrWOZVUSU6JRWK=
DoTc2-4510 NU\kboxNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWrvPJhwUUN3ME21MlQ2OzdzIN88US=> NWTBcFA2W0GQR1XS
LB1047-RCC MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIfTO5BKSzVyPUWuOVU6OzNizszN MV\TRW5ITVJ?
MHH-ES-1 MkjsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHf6eZlKSzVyPUWuOVk6ODdizszN NX3OclJJW0GQR1XS
NMC-G1 NHHnfXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn[0TWM2OD13LkewNlI4KM7:TR?= NEKwdoFUSU6JRWK=
SW1710 M4LYT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRTVwN{S3OVEh|ryP MkTmV2FPT0WU
YAPC NFuybZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYrJR|UxRTVwN{[yNFEh|ryP NEnYOpFUSU6JRWK=
22RV1 MmHtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVrlbXpNUUN3ME21MlgxODF7IN88US=> MnPjV2FPT0WU
COLO-679 Mn70S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWjJR|UxRTVwOEi5OFgh|ryP M4H5c3NCVkeHUh?=
TCCSUP NVLlbmU{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTVwOUOyOVkh|ryP M4HiTXNCVkeHUh?=
C2BBe1 MlzNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTVwOUO5O{DPxE1? NFPIcIpUSU6JRWK=
TE-15 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4faUmlEPTB;Nj6wOlYxPSEQvF2= NYXQUYFOW0GQR1XS
SCLC-21H MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXnQWXhEUUN3ME22MlExQDR|IN88US=> M{XOdXNCVkeHUh?=
EoL-1-cell MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX\2fmZoUUN3ME22MlE3PTZ|IN88US=> NVm2OIh7W0GQR1XS
NKM-1 M363emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1rRRWlEPTB;Nj6xOlcyKM7:TR?= Ml;BV2FPT0WU
NCI-H1304 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2fxSGlEPTB;Nj6yO|QzQCEQvF2= NE\YVI5USU6JRWK=
NB6 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3T1Z2lEPTB;Nj6yPVYzOiEQvF2= MnnSV2FPT0WU
NALM-6 M1PjRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3jmT2lEPTB;Nj6zN|I{KM7:TR?= M1;5SXNCVkeHUh?=
NCI-H522 NGXvcmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTZwM{OzNFYh|ryP NVvjV3R6W0GQR1XS
MV-4-11 Mki3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFHMfI1KSzVyPU[uN|cxPzlizszN NF;iSGlUSU6JRWK=
LB2241-RCC NIHEV2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4\SPWlEPTB;Nj6zPFY3PyEQvF2= M{i0UHNCVkeHUh?=
NCI-H1417 M4TvNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYnoUnRVUUN3ME22MlQxQDR5IN88US=> MVXTRW5ITVJ?
HT-1197 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnHtTWM2OD14LkW3NVIzKM7:TR?= NHLmRXRUSU6JRWK=
P30-OHK MlzVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGX2PZZKSzVyPU[uOlI4PyEQvF2= MXvTRW5ITVJ?
ALL-PO NIjBT4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF\idIpKSzVyPU[uO|E6OTZizszN MX7TRW5ITVJ?
OVCAR-4 M2q2TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3\XRmlEPTB;Nj63OVQxPSEQvF2= Mn7QV2FPT0WU
HCC2157 MnLqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIPyWlVKSzVyPU[uO|c1PzVizszN NH3pZ5VUSU6JRWK=
NCI-H838 M2SwbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX;JR|UxRTZwOU[0PUDPxE1? MWjTRW5ITVJ?
NCI-H1299 NYnONGVQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn7nTWM2OD14Lkm3NFkh|ryP NXzMemdlW0GQR1XS
SW954 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU\1NIs4UUN3ME23MlIxODZ6IN88US=> MkW4V2FPT0WU
NCI-H441 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1PrUGlEPTB;Nz6zOFA3PSEQvF2= NWfrU2hlW0GQR1XS
SK-MEL-2 MnjWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmHaTWM2OD15LkS4N|c{KM7:TR?= MljPV2FPT0WU
KARPAS-45 M3LGOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoC3TWM2OD15Lk[1PVI6KM7:TR?= MVfTRW5ITVJ?
CAL-54 MofqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH3oWGVKSzVyPUeuPFI6PzdizszN MU\TRW5ITVJ?
KYSE-180 NETGW3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYnJR|UxRTdwOEi5OFEh|ryP NWnGbGRkW0GQR1XS
NCI-H187 Mmi3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4DMTGlEPTB;Nz65OVk1PyEQvF2= NXKyeG9XW0GQR1XS
RT-112 NHHQN2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkHmTWM2OD16LkC5Olc4KM7:TR?= M1u1W3NCVkeHUh?=
NCI-H1437 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXzJR|UxRThwMEm3PVUh|ryP MXLTRW5ITVJ?
SNU-449 MnP4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGq2UWFKSzVyPUiuNlgzPzJizszN MWrTRW5ITVJ?
HCC1187 Mn;lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXjJR|UxRThwMkmzPVEh|ryP MoPFV2FPT0WU
NCI-H2030 NWfJd41vT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4L2ZmlEPTB;OD6zO|cyPCEQvF2= NGDxNXFUSU6JRWK=
HuO-3N1 Mmq3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXTJR|UxRThwM{e4OFQh|ryP NXHQZXpDW0GQR1XS
COLO-792 NUC2N3I{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIXG[HlKSzVyPUiuOFE2OjdizszN M3PuPHNCVkeHUh?=
MIA-PaCa-2 MlztS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUjXVohpUUN3ME24Mlg2PTB6IN88US=> MXrTRW5ITVJ?
SK-N-FI MmfFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnH6TWM2OD17LkC0NlUh|ryP M333WXNCVkeHUh?=
MMAC-SF M33vXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{fVNmlEPTB;OT6wPVc2OSEQvF2= NXTNPXhbW0GQR1XS
NCI-H28 M2fXWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIm0boNKSzVyPUmuNVA1PjlizszN MmTrV2FPT0WU
ETK-1 NF31WFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIjRWnlKSzVyPUmuNlk6PzRizszN NHXhdmNUSU6JRWK=
NCI-H1993 MkPqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3jiSmlEPTB;OT60OFI3OSEQvF2= MnfOV2FPT0WU
no-11 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3LsOWlEPTB;OT60O|EzKM7:TR?= M2TKfHNCVkeHUh?=
ChaGo-K-1 M3G4UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnr1TWM2OD17LkWxOVg{KM7:TR?= NXLVc49LW0GQR1XS
NCCIT MljUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV:3fI1VUUN3ME25MlU{OTZ7IN88US=> M16yXXNCVkeHUh?=
SAS NXXwSGZDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnTRTWM2OD1zMD6yOFgh|ryP NYH0VWZKW0GQR1XS
A673 NGm2cGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2rvSGlEPTB;MUCuN|cxPCEQvF2= NEjO[2lUSU6JRWK=
NCI-H1522 M4f1VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV3JR|UxRTFyLkO3NFch|ryP MmfLV2FPT0WU
NCI-H810 M4XKT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{DBRmlEPTB;MUCuN|kxPyEQvF2= NEnP[3JUSU6JRWK=
IST-MES1 NUnneHA4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUTJR|UxRTFyLkS1OlQh|ryP NEPr[XVUSU6JRWK=
GR-ST M1uzbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1LZUGlEPTB;MUCuOVAzPCEQvF2= NU\nUoUxW0GQR1XS
SUP-T1 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX;yWYlrUUN3ME2xNE44OzF5IN88US=> NFnscWFUSU6JRWK=
NB5 NIDUVHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1HLN2lEPTB;MUCuPVAzOiEQvF2= NIXCeXpUSU6JRWK=
MZ1-PC MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVPOTmdVUUN3ME2xNE46PTdzIN88US=> NGHxdVVUSU6JRWK=
SK-CO-1 NWe1N3I3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2jHR2lEPTB;MUCuPVk{OSEQvF2= MYLTRW5ITVJ?
Capan-2 MnvSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUjJR|UxRTFzLkOxPVgh|ryP NV;kRlRiW0GQR1XS
697 NUfJb4lZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXLJR|UxRTFzLk[3OVch|ryP NHfQRoVUSU6JRWK=
REH M{PPXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYnJR|UxRTFzLke0OVEh|ryP NHnYdnpUSU6JRWK=
GI-1 NUO5TWRKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NELuS25KSzVyPUGxMlg3OTVizszN NFrTclNUSU6JRWK=
BB65-RCC NELQOphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHLXUJhKSzVyPUGyMlA6OTZizszN NYXuepllW0GQR1XS
NCI-H1651 NWnIPIVTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVjJR|UxRTF{LkK0O|gh|ryP MYDTRW5ITVJ?
NCI-H1618 NUT1UGRkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYfJR|UxRTF{LkO5O|Yh|ryP NXTlTXdqW0GQR1XS
NCI-H2081 MmLXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkKxTWM2OD1zMj62NVQyKM7:TR?= NICw[I9USU6JRWK=
GCIY M1X0emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVTSdFdOUUN3ME2xNk44OjF|IN88US=> MXHTRW5ITVJ?
NY MlO3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnTvTWM2OD1zMz6wOlQ{KM7:TR?= NXPEfYdEW0GQR1XS
PANC-03-27 NFnVWmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoqzTWM2OD1zMz6wPFA4KM7:TR?= NGi1RoNUSU6JRWK=
BHY NHvXPI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2LOdWlEPTB;MUOuNlEzOSEQvF2= M2LBRnNCVkeHUh?=
SK-OV-3 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{HVOmlEPTB;MUOuN|c3OyEQvF2= NYHrTHQ3W0GQR1XS
5637 M3rmUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYj4WIF2UUN3ME2xN{44PzV7IN88US=> MoGyV2FPT0WU
LC-1F MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;OVGlEPTB;MUSuNFM2PiEQvF2= M1XTW3NCVkeHUh?=
SNB75 NIroeplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUHJR|UxRTF2LkCzPFMh|ryP NEToTIhUSU6JRWK=
CHP-212 NXzDR4R1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmDMTWM2OD1zND6wOFY1KM7:TR?= M1HnOHNCVkeHUh?=
HT-1376 NX;meIxqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHPWV2lKSzVyPUG0MlEyOjZizszN M3v5cXNCVkeHUh?=
MONO-MAC-6 M2PKbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUTJR|UxRTF2LkG1NFIh|ryP M3LpfXNCVkeHUh?=
CA46 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoHHTWM2OD1zND6xPFI4KM7:TR?= M{LSO3NCVkeHUh?=
SCC-15 MlXaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV\QcG9tUUN3ME2xOE42PTh|IN88US=> NXL4OW5nW0GQR1XS
ATN-1 Mo\yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2rjSWlEPTB;MUSuOlYzPyEQvF2= NV7ZXJFoW0GQR1XS
NCI-H2405 MoixS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M33RSmlEPTB;MUSuPFE2PyEQvF2= MoPQV2FPT0WU
NCI-H716 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVPJR|UxRTF2Lki0PVMh|ryP M1XDc3NCVkeHUh?=
SW620 NXrQSIRZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH:0UGZKSzVyPUG0MlkxOTRizszN M4H1e3NCVkeHUh?=
NCI-H226 NXvN[3JJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4XyXmlEPTB;MUSuPVA5PSEQvF2= MXjTRW5ITVJ?
SW962 Mm\PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYfj[Ws5UUN3ME2xOE46PDN{IN88US=> MX;TRW5ITVJ?
KYSE-150 NEXFTI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3LwdGlEPTB;MUSuPVU2KM7:TR?= NHzWdJRUSU6JRWK=
OCUB-M NULXVXFnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE\0N|VKSzVyPUG0Mlk5QDNizszN M{XIZnNCVkeHUh?=
ES7 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13vZ2lEPTB;MUWuNFk5PCEQvF2= MX3TRW5ITVJ?
SW1463 M2Pab2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoW0TWM2OD1zNT60NlI{KM7:TR?= NUP3W49SW0GQR1XS
CAKI-1 M4\6e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4[zWmlEPTB;MUWuOVM1PiEQvF2= NGLTU2tUSU6JRWK=
MKN28 NGS4dYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkfzTWM2OD1zNT61OFc6KM7:TR?= MWTTRW5ITVJ?
SW13 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTF3Lk[xPEDPxE1? NEDNUmxUSU6JRWK=
A3-KAW MonmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MorBTWM2OD1zNT65Olk4KM7:TR?= NYW4[pVUW0GQR1XS
LU-65 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmL3TWM2OD1zNT65O|Y5KM7:TR?= M{flenNCVkeHUh?=
Calu-1 M4\nZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTF4LkCzOlgh|ryP M{fKPXNCVkeHUh?=
ST486 Ml;WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{PsOmlEPTB;MU[uNFQ{OSEQvF2= Mk\SV2FPT0WU
BB30-HNC NWmxOoV5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEXGfWFKSzVyPUG2MlEzPDZizszN NE[2d|BUSU6JRWK=
EGI-1 NHnIeHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFnObVZKSzVyPUG2MlQ1PiEQvF2= NVj0ZVZMW0GQR1XS
SH-4 M{C5cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFiw[nhKSzVyPUG2MlQ4OzFizszN NF7PSG5USU6JRWK=
MN-60 NFrkW5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEXVcYZKSzVyPUG3MlIzQTdizszN MU\TRW5ITVJ?
MPP-89 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYDJR|UxRTF5LkK0OVkh|ryP NUTaeJFMW0GQR1XS
A2780 NXrqWpJrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\UTWM2OD1zNz60NVM6KM7:TR?= MnLGV2FPT0WU
Daoy M1LBS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTF5LkS2PVUh|ryP NH3q[lhUSU6JRWK=
NCI-H2126 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV3JR|UxRTF5LkS3O|Eh|ryP NHTFclVUSU6JRWK=
NCI-H1563 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXnJR|UxRTF5LkS5NVch|ryP MVfTRW5ITVJ?
8-MG-BA NWHOfIhZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTF5Lk[2OFgh|ryP NH;hRohUSU6JRWK=
786-0 NFjRRmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlTiTWM2OD1zNz64N|U{KM7:TR?= NEXTPXFUSU6JRWK=
AM-38 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWnJR|UxRTF5LkmzNFYh|ryP NW\sdZQ2W0GQR1XS
COLO-824 NIjKcoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTF6LkS0N|Yh|ryP M1L2U3NCVkeHUh?=
SK-MEL-30 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkHiTWM2OD1zOD61NFgzKM7:TR?= NHWySI9USU6JRWK=
CESS MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGSzdW1KSzVyPUG4Mlc3ODlizszN M2rre3NCVkeHUh?=
BL-70 MmTwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHjtNJhKSzVyPUG4MlgyPTZizszN MknEV2FPT0WU
NCI-H2170 NH\XOFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{D5OmlEPTB;MUiuPVE4QSEQvF2= MkTmV2FPT0WU
HT-3 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTF6Lkm4N{DPxE1? MVnTRW5ITVJ?
BOKU NFj2cWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1jvTWlEPTB;MUmuNFM5OSEQvF2= M1HP[HNCVkeHUh?=
HPAF-II NWGzXXA5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWXIcIt{UUN3ME2xPU4{ODF3IN88US=> M{\VNnNCVkeHUh?=
KGN NU\STlR6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEP3SG5KSzVyPUG5MlQ4PjVizszN MWLTRW5ITVJ?
MC-CAR NXHueYM2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFKyZmpKSzVyPUG5MlY{OTNizszN NUSwRoxzW0GQR1XS
BHT-101 M1Xxd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTF7Lke3O{DPxE1? MVPTRW5ITVJ?
SW1783 M1jvZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYTJR|UxRTF7Lke4NFYh|ryP MX\TRW5ITVJ?
KP-N-YN NGD4UHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEO2RpBKSzVyPUKwMlAzPjJizszN MmrrV2FPT0WU
LU-165 NHPrPXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MULJR|UxRTJyLkW1O|Eh|ryP Ml;CV2FPT0WU
GOTO NVjZT2V7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2f6SWlEPTB;MkCuOlQ2OSEQvF2= NYTBdpRLW0GQR1XS
EFM-19 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYTFeoxJUUN3ME2yNU4xPzF4IN88US=> NIDCb5lUSU6JRWK=
CTV-1 M4LJe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW\UZ|NSUUN3ME2yNU4yODV2IN88US=> MoPsV2FPT0WU
HEL Mk\nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2[wZmlEPTB;MkGuOFIyPiEQvF2= M4L3dnNCVkeHUh?=
SNU-C2B NVfURWZDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3ru[WlEPTB;MkGuOFI3KM7:TR?= NF:5SGlUSU6JRWK=
ECC4 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVfJR|UxRTJzLkewO{DPxE1? MWDTRW5ITVJ?
NEC8 M4LGcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXPJR|UxRTJzLkizOlgh|ryP MUTTRW5ITVJ?
KMOE-2 NHjvZndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlfmTWM2OD1{MT64PVIyKM7:TR?= M2fmWXNCVkeHUh?=
NCI-H524 M1K2NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmD3TWM2OD1{Mj6wPFA5KM7:TR?= M{facnNCVkeHUh?=
WSU-NHL NVjGXVJGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MljTTWM2OD1{Mj6xOVc4KM7:TR?= M4DEeXNCVkeHUh?=
SF126 NXTCfXo6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE\2R4xKSzVyPUKyMlI1PjlizszN MVjTRW5ITVJ?
HOP-92 NXLY[lNyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYTJR|UxRTJ{LkOxOlch|ryP Mn\4V2FPT0WU
CTB-1 NH\RdYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{HQZ2lEPTB;MkKuOFY4PyEQvF2= M4PYeHNCVkeHUh?=
KYSE-270 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\BZldKSzVyPUKyMlk{PTdizszN MWjTRW5ITVJ?
SK-MEL-24 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXvJR|UxRTJ|LkG4O{DPxE1? MVTTRW5ITVJ?
Calu-3 NUewWItLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnjVTWM2OD1{Mz6yNVI5KM7:TR?= MXrTRW5ITVJ?
GAMG M1PU[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{XYcGlEPTB;MkOuNlM3PyEQvF2= NUTwXHlUW0GQR1XS
SW1573 NF3Ed2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\STWM2OD1{Mz63OFE2KM7:TR?= MkHhV2FPT0WU
MHH-NB-11 M1XWZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmC3TWM2OD1{ND6wNVk1KM7:TR?= NU\lTmM4W0GQR1XS
TK10 MkTLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXrp[HVuUUN3ME2yOE42ODF|IN88US=> NULwU5VsW0GQR1XS
LB373-MEL-D MmLBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2nKUWlEPTB;MkSuOlA3PCEQvF2= MnL5V2FPT0WU
KALS-1 NU\FeVhxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVrsZXk5UUN3ME2yOE44OzJ5IN88US=> NXXUWHF4W0GQR1XS
HUTU-80 MnOyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFPHbVdKSzVyPUK1MlgxOzJizszN MV;TRW5ITVJ?
HuP-T3 NHPsSZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUDXTFBjUUN3ME2yOk4yPjd2IN88US=> MX7TRW5ITVJ?
OE19 M3\FN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVrEO5ZqUUN3ME2yOk4zOTV|IN88US=> MluzV2FPT0WU
J82 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFG4cXFKSzVyPUK2MlI1PzFizszN M{LleHNCVkeHUh?=
DU-4475 MkDrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYjKWm1lUUN3ME2yOk4{QDF7IN88US=> NH3mcndUSU6JRWK=
DMS-53 NGPWcHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1fIcmlEPTB;Mk[uOVE{QCEQvF2= NED6PFBUSU6JRWK=
COLO-741 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWLpb215UUN3ME2yOk45OzR2IN88US=> NYDNflVoW0GQR1XS
SW48 NHPpcVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4X4U2lEPTB;Mk[uPFgzKM7:TR?= Mn7UV2FPT0WU
IGR-1 NETPdo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4W3eWlEPTB;Mk[uPVM{PCEQvF2= MWrTRW5ITVJ?
639-V NH3PS|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;y[XUzUUN3ME2yO{4xOjR3IN88US=> MofrV2FPT0WU
LK-2 NV;wU21FT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUfJR|UxRTJ5LkSxOFEh|ryP NXm5bYh2W0GQR1XS
NCI-H2347 MojzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXjJR|UxRTJ5Lkm2PVkh|ryP MmnhV2FPT0WU
NCI-H2228 MnPIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEG1UHZKSzVyPUK4MlA6ODVizszN NX\KS4JWW0GQR1XS
LS-123 MlLDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFzGVmZKSzVyPUK4MlEzPjJizszN MXfTRW5ITVJ?
U031 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRTJ6LkK1NkDPxE1? MlT2V2FPT0WU
NCI-H1792 MoDkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEC0UWRKSzVyPUK4MlQ4OjFizszN MV;TRW5ITVJ?
NCI-H2087 M2TU[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4DXNWlEPTB;MkiuO|U2OiEQvF2= NYHDfpNMW0GQR1XS
NCI-H2342 MlX2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MljZTWM2OD1{OT61NlA5KM7:TR?= NXzycWlsW0GQR1XS
SW626 NIjtTXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWLJ[3c1UUN3ME2yPU44PTZizszN NHKyNXJUSU6JRWK=
LB2518-MEL NYS5dGMyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnjDTWM2OD1{OT64NVUh|ryP M1rmbHNCVkeHUh?=
RXF393 MkjTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWXEdlNlUUN3ME2zNE4xQTV{IN88US=> NEDDVlJUSU6JRWK=
LC4-1 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE\5PJpKSzVyPUOwMlMxQTJizszN NIrDNWlUSU6JRWK=
NCI-H1694 M3v1Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXrJR|UxRTNyLk[2NlQh|ryP NIHTV41USU6JRWK=
K5 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGnoTJJKSzVyPUOwMlk4ODJizszN MYHTRW5ITVJ?
HDLM-2 NV[5dpBZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4rQS2lEPTB;M{CuPVczPSEQvF2= NWr1OXlYW0GQR1XS
BCPAP NVfmblJtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkPCTWM2OD1|MT64N|c6KM7:TR?= MnzCV2FPT0WU
BC-3 NXW2d5V7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmmxTWM2OD1|Mj6xOFA{KM7:TR?= NHf6N45USU6JRWK=
LB996-RCC NHLERVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVzDWG1jUUN3ME2zNk4zOzV6IN88US=> MnTPV2FPT0WU
NCI-H2009 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2HRbWlEPTB;M{KuOFk5OSEQvF2= M3HVdXNCVkeHUh?=
HTC-C3 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoPXTWM2OD1|Mz63OVE6KM7:TR?= MoHtV2FPT0WU
LAMA-84 MljLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVv3fI4xUUN3ME2zOE41PDB5IN88US=> NFjVNWFUSU6JRWK=
CCRF-CEM MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1HVOWlEPTB;M{SuOVcyPSEQvF2= NGPMV2hUSU6JRWK=
AN3-CA NFvkSoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3uxRWlEPTB;M{WuNFU3QCEQvF2= M3vmfXNCVkeHUh?=
NCI-H1734 M{LWfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NID5R|RKSzVyPUO1MlI2PjFizszN MYfTRW5ITVJ?
Ca-Ski M3PzbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1S5[WlEPTB;M{WuOFExOSEQvF2= MUTTRW5ITVJ?
U-266 NIDk[FBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHq5OolKSzVyPUO1MlYyOTRizszN M3GwNnNCVkeHUh?=
SBC-5 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFTBb5hKSzVyPUO1Mlc4QDFizszN NX;XRmIxW0GQR1XS
GT3TKB M4DONGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGHuOVhKSzVyPUO3MlEyPSEQvF2= M2jicnNCVkeHUh?=
MDA-MB-175-VII M3fFOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI\zV4hKSzVyPUO3MlIzPDhizszN NVLyfXFsW0GQR1XS
PFSK-1 MnzpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHTNUIFKSzVyPUO3MlI1OzVizszN MXzTRW5ITVJ?
IMR-5 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYOxZ4tTUUN3ME2zO{4zPDh5IN88US=> Mnv4V2FPT0WU
Daudi M1TaOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHfXO4FKSzVyPUO3MlM2QTdizszN MoD2V2FPT0WU
A498 NFrWSGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn\YTWM2OD1|Nz63NlE5KM7:TR?= NVu3bVFoW0GQR1XS
SCC-4 NUDWdHNuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4fGUmlEPTB;M{euO|g1OyEQvF2= MoXSV2FPT0WU
COLO-680N M4rXTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MULJR|UxRTN6LkK4PFUh|ryP NVn6WJVIW0GQR1XS
SK-MES-1 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{\C[mlEPTB;M{iuN|IyPSEQvF2= M37Ub3NCVkeHUh?=
SR NY\EZ5lHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIrxNWRKSzVyPUO4MlU1QTVizszN M17BbnNCVkeHUh?=
LNCaP-Clone-FGC NH\McWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF3pSWhKSzVyPUO4MlU3OzdizszN NV7YdJBGW0GQR1XS
SK-HEP-1 NWLMbVZpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHTaTIdKSzVyPUO4Mlc5OjJizszN MV3TRW5ITVJ?
BPH-1 NFjkeWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUPJR|UxRTN6LkizNlkh|ryP NIrhZ4hUSU6JRWK=
NCI-H1755 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkDCTWM2OD1|OT61PFE4KM7:TR?= M{DHeHNCVkeHUh?=
LXF-289 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mof0TWM2OD1|OT64NFg1KM7:TR?= MXPTRW5ITVJ?
SW1088 NIfDZ|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4rte2lEPTB;NECuNlExPyEQvF2= NHj6XI5USU6JRWK=
MOLT-4 NULmXZBkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYfJR|UxRTRyLkK5NFEh|ryP NI\O[YdUSU6JRWK=
AsPC-1 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\tTWM2OD12MD60OVg{KM7:TR?= M3i3VHNCVkeHUh?=
HOP-62 NIfZW4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFvyc|dKSzVyPUSwMlY2PjhizszN MkHxV2FPT0WU
A172 Mo\FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWXJR|UxRTRyLki1NVEh|ryP MmPNV2FPT0WU
SN12C MnjvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFnQXodKSzVyPUSwMlk{QDVizszN NImxZWhUSU6JRWK=
MDA-MB-231 MnLhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3X3c2lEPTB;NECuPVg6QCEQvF2= M2LEN3NCVkeHUh?=
RPMI-2650 NFHmdHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHLXWIJKSzVyPUSxMlE2QTNizszN Mk\IV2FPT0WU
KYSE-140 NVrmRZNYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWTsT|JTUUN3ME20NU45OTJ|IN88US=> M2W4[nNCVkeHUh?=
KINGS-1 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoDQTWM2OD12Mj60Olk4KM7:TR?= MYfTRW5ITVJ?
HSC-3 M3LMeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3Twe2lEPTB;NEKuOlY3OSEQvF2= M{TRNnNCVkeHUh?=
PC-14 NUDDNHFPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{DhO2lEPTB;NEOuNVg5OiEQvF2= NUXEU21EW0GQR1XS
COR-L105 NYDXO3JCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{T2VmlEPTB;NEOuOlUxOiEQvF2= MVPTRW5ITVJ?
BE-13 NWrEPGJuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYnJR|UxRTR2LkKzO|Eh|ryP MYLTRW5ITVJ?
NCI-H661 MoH4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHXUeWpKSzVyPUS0MlI6PThizszN MnPvV2FPT0WU
IST-MEL1 NHHIWlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkfVTWM2OD12ND6zOVk6KM7:TR?= M3m3RXNCVkeHUh?=
HCC1806 NU\P[GdzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUnJR|UxRTR2LkW4O|Mh|ryP MUfTRW5ITVJ?
COLO-800 Ml\KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWHsSIZqUUN3ME20OE45PDV|IN88US=> NXnWRmZiW0GQR1XS
IST-SL2 Mo\oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH7jeFZKSzVyPUS1MlEzPDdizszN NXvQelRzW0GQR1XS
8305C MnvuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF3S[GxKSzVyPUS1MlMxQSEQvF2= MmPSV2FPT0WU
UACC-62 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\LTWM2OD12Nj6yPFc2KM7:TR?= NV;SVpk2W0GQR1XS
COR-L23 NF\qVWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV;EZnZEUUN3ME20O{4yQTlizszN NU\se|dpW0GQR1XS
EFE-184 NFG5RnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3\aTGlEPTB;NEeuN|g5KM7:TR?= NU[zXIpyW0GQR1XS
DMS-114 Mm\OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3ewOGlEPTB;NEeuOFE1QSEQvF2= MoDoV2FPT0WU
KYSE-520 MlLDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1XEe2lEPTB;NEiuOVMyPSEQvF2= MmfSV2FPT0WU
SNG-M Mni4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHLiOXlKSzVyPUS5MlQ{PCEQvF2= MnrTV2FPT0WU
A2058 NVLDW5M1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkX1TWM2OD12OT60PFg2KM7:TR?= NEjSe21USU6JRWK=

... Click to View More Cell Line Experimental Data

In vivo試験 OSI-906 inhibits tumor growth in an IGF-1R-driven xenograft mouse model, with 100% TGI and 55% regression at a dose of 75 mg/kg and 60% TGI and no regression at a dose of 25 mg/kg. OSI-906 administration induces different elimination half-lives of itself in dog, rat and mice, the elimination half-lives are 1.18 hours, 2.64 hours and 2.14 hours, respectively. OSI-906 administration at different single dose once-daily in femal Sprague-Dawley rat and femal CD-1 mouse reveal that the Vmax is not dose-proportional to OSI-906 dose. OSI-906 elevates the blood glucose levels at a dose of 25 mg/kg after 12 days administration. OSI-906 administration at a single dose of 75 mg/kg in IGF-1R-driven full-length human IGF-1R (LISN) xenograft mouse model achieve maximal inhibition of IGF-1R phosphorylation (80%) between 4 and 24 hours with plasma drug concentrations of 26.6-4.77 μM. [1] OSI-906 administered as a single dose of at 60 mg/kg in NCI-H292 xenografts mice inhibits uptake of glucose at 2, 4, and 24 hours post-treatment in vivo. OSI-906 inhibits the growth of tumors in NCI-H292 xenograft mouse model. [2]
臨床試験 OSI-906 is currently under a Phase III clinical trial in adrenocortical carcinoma (ACC).
特集

プロトコル (参考用のみ)

キナーゼアッセイ: [1]

Protein kinase biochemical assays Protein kinase assays are either performed in-house by ELISA-based assay methods (IGF-1R, IR, EGFR and KDR) or at Upstate Inc. by a radiometric method with ATP at 100 µM concentration. In-house ELISA assays use poly(Glu:Tyr) as the substrate bound to the surface of 96-well assay plates and phosphorylation is detected using an antiphosphotyrosine antibody conjugated to horseradish peroxidase. The bound antibody is quantified using ABTS as the peroxidase substrate by measuring absorbance at 405 / 490 nm. All assays use purified recombinant kinase catalytic domains. Recombinant enzymes of human IGF-1R or EGFR are expressed as an NH2-terminal glutathione S-transferase fusion protein in insect cells and are purified in house. IC50 values are determined from the sigmoidal dose–response plot of percent inhibition versus log10 compound concentration. A minimum of three measurements, performed in duplicate, are carried out with in-house assays unless otherwise indicated. OSI-906 at a concentration of 1 µM is profiled versus a panel of kinases using the ProfilerProTM Kinase Selectivity Assay Kit.

細胞アッセイ: [1]

細胞株 MCF7, NCI-H292, Colo-205, HT29, H358, H1703, BxPC3, A673, SW620, DU4475, HepG2 and Hepa-1, RKO 3T3/hulGF-IR and H292 cells
濃度 0.02-0.8 μM
反応時間 3 days
実験の流れ For assays of cell proliferation, cells are seeded into 96-well plates in appropriate media containing FCS 10% and incubated for 3 days in the presence of OSI-906 at various concentrations. Inhibition of cell growth is determined by luminescent quantitation of intracellular ATP content using CellTiterGlo. Data is presented as a fraction of maximal proliferation, calculated by dividing the cellular density in the presence of varying concentrations of OSI-906 by the cellular density of control cells treated with vehicle (DMSO) only.

動物実験: [1]

動物モデル IGF-1R-driven full-length human IGF-1R (LISN) xenograft mouse model
製剤 25 mM tartaric acid
投薬量 25 mg / kg and 75 mg / kg
投与方法 Orally administrated at once-daily oral dose for 14 days

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDogMonkeyBaboon
Weight (kg)0.020.151.80.40.0810312
Body Surface Area (m2)0.0070.0250.150.050.020.50.240.6
Km factor361285201220
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

参考

化学情報

Download OSI-906 (Linsitinib) SDF
分子量 421.49
化学式

C26H23N5O

CAS No. 867160-71-2
保管 2年-20℃
6月-80℃in solvent
別名 N/A
溶解度 (25°C) * In vitro DMSO 84 mg/mL (199.29 mM)
<1 mg/mL (<1 mM)
エタノール <1 mg/mL (<1 mM)
In vivo 30% PEG 400+0.5% Tween 80+5% Propylene glycol 30mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
化学名 (1s,3s)-3-(8-amino-1-(2-phenylquinolin-7-yl)imidazo[1,5-a]pyrazin-3-yl)-1-methylcyclobutanol

カスタマーフィードバック (3)


Click to enlarge
Rating
Source Cancer Res, 2013, 73, 834-843. OSI-906 (Linsitinib) purchased from Selleck
Method Cell proliferation and growth assays
Cell Lines PFR3 cells
Concentrations 1 μM
Incubation Time
Results The IC50 of PFR3 cells for PF299804 was more than 100 fold lower with the combination of OSI-90 than with PF00299804 alone.

Click to enlarge
Rating
Source Cancer Res, 2011, 71, 6773-84. OSI-906 (Linsitinib) purchased from Selleck
Method [18 F]FDG –PET/ Western blot
Cell Lines MCF-7 cells/athymic mice
Concentrations 50 mg/kg/day
Incubation Time 6 weeks
Results mice without palpable tumors were randomized to treatment with vehicle or OSI-906. Six of 20 control mice (30%) developed tumors, whereas none of the 20 OSI-906–treated mice did (Fig. A). OSI-906 inhibited tumor growth compared with vehicle (Fig. B; P < 0.05). OSI-906–treated tumors exhibited markedly lower levels of phosphorylated IGF-IR, InsR, IRS-1, AKT, and S6 compared with vehicle controls (Fig. C). FDG uptake was significantly decreased 4 hours after a single dose of OSI-906 com-pared with baseline (Fig. D)

Click to enlarge
Rating
Source OSI-906 (Linsitinib) purchased from Selleck
Method Flow cytometry/ Western Blotting
Cell Lines CLL B cells
Concentrations 1 µM
Incubation Time 24 h
Results three structurally unrelated IGF1R inhibi tors AG1024, Picropodophyllin (PPP) and linsitinib significantly reduced the cellular viability of primary CLL cells ( Figure A) and reduced levels of phosphorylated IGF1R and IRS-1 (Figure B,C). AG1024, which showed the strongest effect on viability, caused a dose-dependent decrease in the levels of phosphorylated Src, PI3K, Akt, MEK and ERK (Figure D).

文献中の引用 (15)

技術サポート&よくある質問(FAQ)

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

電話番号: +1-832-582-8158 Ext:3月曜日〜金曜日 9:00 AM–5:00 PM (米国中部標準時)

他の質問がある場合は、お気軽くお問合せください。

* 必須

Related IGF-1R 阻害剤

  • Picropodophyllin (PPP)

    Picropodophyllin (PPP) is a selective IGF-1R inhibitor with IC50 of 1 nM. Phase 1/2.

  • Erlotinib

    Erlotinib is an EGFR inhibitor with IC50 of 2 nM, >1000-fold more sensitive for EGFR than human c-Src or v-Abl.

  • R428 (BGB324)

    R428 (BGB324) is an inhibitor of Axl with IC50 of 14 nM, >100-fold selective for Axl versus Abl. Selectivty for Axl is also greater than Mer and Tyro3 (50-to-100- fold more selective) and InsR, EGFR, HER2, and PDGFRβ (100- fold more selective).

  • Pexidartinib (PLX3397)

    Pexidartinib (PLX3397) is an oral, potent mutil-targeted receptor tyrosine kinase inhibitor of CSF-1R, Kit, and Flt3 with IC50 of 20 nM, 10 nM and 160 nM, respectively. Phase 3.

  • BMS-536924

    BMS-536924は、ATP競争的IGF-IRとIR阻害剤で、IC50 がそれぞれ 100 nM と 73 nMです。

  • NVP-AEW541

    NVP-AEW541は、IGF-IRとInsRの二重阻害剤で、IC50 がそれぞれ 86 nM と 140 nMです。

  • NVP-ADW742

    NVP-ADW742は、0.17のμMのIC50によるIGF1R阻害剤です。

  • GSK1904529A

    GSK1904529Aは選択性阻害剤、(IGF-IR) と (IR)を抑制する時、 IC50が それぞれ27 nM と 25 nMになる.

  • BMS-754807

    BMS-754807は、IGF1R/IR家族キナーゼの強力で可逆的な阻害剤で、 IGF-1RIRMetTrkATrkBを妨げ、IC50 がそれぞれ 1.8 nM、1.7 nM、5.6 nM、7.4 nM 、 4.1 nMです。

    Features:Muti-inhibitor of the IGR-1R/IR family.

最近チェックしたアイテム

Tags: OSI-906 (Linsitinib)を買う | OSI-906 (Linsitinib)供給者 | OSI-906 (Linsitinib)を購入する | OSI-906 (Linsitinib)費用 | OSI-906 (Linsitinib)生産者 | オーダーOSI-906 (Linsitinib) | OSI-906 (Linsitinib)代理店
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
お問い合わせ